The experimental vaccine AstraZenece showed quite encouraging results in pig tests when the animals were given two doses. After two doses, the antibody response was much higher than after just one. The vaccine has also been tested on six monkeys and found to have developed antibodies within 28 days at the latest.
An experimental vaccine against the new coronavirus, manufactured by the pharmaceutical company AstraZeneca, has shown encouraging results in tests on pigs, especially if the animals have received two doses. Re-administration of the vaccine triggered a much greater antibody response.
The results of the study, published by the British Pirbright Institute on Tuesday, show that the initial dose, followed by another, ‘stimulating’ dose of the vaccine, causes a much stronger immune system response than a single application. This suggests that a two-dose approach may be more effective in providing protection against covid-19, a disease caused by the new coronavirus, Reuters reports .
“Researchers have noticed an increase in neutralizing (Slovenian also neutralizing, op. Cit.) Antibodies that bind to the virus in a way that blocks infection,” the Pirbright team wrote in a press release. They added, however, that it is not yet known what level of immune response will be needed to protect people.
The ChAdOx1 nCoV-19 vaccine, also known as AZD1222, was first developed by scientists at Oxford University, who are now working with AstroZeneca to develop and manufacture the vaccine.
“These results are encouraging for now that the use of two doses increases the response of antibodies that can neutralize the virus, but the response in humans is important,” said Bryan Charleston , director of Pirbright.
The AZD1222 is already being tested on humans, and AstraZeneca hopes to have the first performance results later this year. The vaccine has also been tested on six monkeys, with some monkeys receiving one dose developing antibodies within 14 days, all within 28 days at the latest.
All over the world, researchers and scientists are working with pharmaceutical companies to accelerate the development of vaccines. Currently, more than 100 potential vaccines are already being tested, and they hope at least one of these will help curb a pandemic that has claimed more than 477,000 lives, according to the latest figures.
Stephen Griffin , an associate professor at the University of Leeds who has not been directly involved in AstraZeneca research, says it is “encouraging progress that shows that a two-dose strategy gives much better results than a single-dose strategy” . “While these studies will have to be repeated in humans, the results are pretty good for now,” he added.